FDA leaves biosim trial data off product labels in new guidance

The FDA is out with new guidance for labeling biosimilar drugs--and it may not make some drugmakers happy. Regulators dismissed pharma's request that the label describe the clinical data copycats used for approval purposes. Instead, the FDA will rely heavily on the reference products' labels, focusing on the info physicians will need to use the product. Guidance (PDF) | More from FierceBiotech

Suggested Articles

Former FDA Commissioner Scott Gottlieb says 40% of the population needs to be vaccinated to achieve COVID-19 herd immunity.

CanSino Bio, Moderna and a collaboration between Oxford Univeristy and AstraZeneca are frontrunners, but they all face hurdles shared and unique.

Novavax will shell out $167 million for Czech manufacturer Praha Vaccines in a move to boost production of a COVID-19 vaccine past 1 billion doses.